Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Capital Expenditures (2021 - 2025)

Senti Biosciences (SNTI) has 5 years of Capital Expenditures data on record, last reported at $196000.0 in Q2 2025.

  • For Q2 2025, Capital Expenditures changed N/A year-over-year to $196000.0; the TTM value through Sep 2025 reached $181000.0, down 98.5%, while the annual FY2023 figure was $12.0 million, 70.9% down from the prior year.
  • Capital Expenditures reached $196000.0 in Q2 2025 per SNTI's latest filing, up from -$15000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $14.2 million in Q3 2022 and bottomed at -$10.2 million in Q3 2023.
  • Average Capital Expenditures over 5 years is $4.5 million, with a median of $4.8 million recorded in 2023.
  • Peak YoY movement for Capital Expenditures: surged 1423.71% in 2022, then crashed 171.64% in 2023.
  • A 5-year view of Capital Expenditures shows it stood at $4.0 million in 2021, then soared by 114.13% to $8.5 million in 2022, then skyrocketed by 41.04% to $12.0 million in 2023, then crashed by 100.12% to -$15000.0 in 2024, then surged by 1406.67% to $196000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $196000.0 in Q2 2025, -$15000.0 in Q4 2024, and $15000.0 in Q1 2024.